Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving Average – What’s Next?

Champions Oncology, Inc. (NASDAQ:CSBR) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.46 and traded as low as $5.90. Champions Oncology shares last traded at $6.1990, with a volume of 6,648 shares.

Analyst Ratings Changes

Separately, Weiss Ratings cut Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Champions Oncology presently has an average rating of “Sell”.

Champions Oncology Price Performance

The company has a 50-day simple moving average of $5.95 and a 200-day simple moving average of $6.46. The stock has a market cap of $86.10 million, a PE ratio of -38.74 and a beta of 0.43.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CSBR. Goldman Sachs Group Inc. purchased a new position in Champions Oncology in the first quarter worth $201,000. Jane Street Group LLC purchased a new position in Champions Oncology in the first quarter worth $200,000. Acadian Asset Management LLC raised its position in Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 8,814 shares in the last quarter. XTX Topco Ltd purchased a new position in Champions Oncology in the second quarter worth $103,000. Finally, Vanguard Group Inc. raised its position in Champions Oncology by 1.9% in the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after acquiring an additional 6,229 shares in the last quarter. Hedge funds and other institutional investors own 41.30% of the company’s stock.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.